Related Experiment Videos
FK506 enhanced osteoblastic differentiation in mesenchymal cells
Lin Tang1, Sohei Ebara, Satoshi Kawasaki
1Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan. soebara@hsp.md.shinshu-u.ac.jp
Cell Biology International
|January 10, 2002
Summary
The immunosuppressant FK506 promotes osteoblastic differentiation in mesenchymal cells. It also enhances bone morphogenetic protein-4 (BMP-4) induced osteoblastic differentiation, suggesting potential applications in bone tissue regeneration.
Area of Science:
- Biochemistry
- Cell Biology
- Regenerative Medicine
Background:
- Bone morphogenetic protein (BMP) is crucial for osteogenic differentiation of mesenchymal cells.
- Immunosuppressants have shown potential to induce osteoblastic differentiation, relevant for bone tissue transplantation.
Purpose of the Study:
- To investigate the effect of FK506, a clinical immunosuppressant, on osteoblastic differentiation.
- To assess the combined effect of FK506 and BMP-4 on osteoblastic and mesenchymal cell differentiation.
Main Methods:
- Assessed alkaline phosphatase (ALP) activity, a marker of osteoblast differentiation.
- Evaluated mRNA levels of ALP and osteocalcin.
- Utilized osteoblast-like and other mesenchymal cells.
Main Results:
- FK506 induced a dose- and time-dependent increase in ALP activity.
- FK506 alone stimulated osteoblastic differentiation.
- FK506 enhanced BMP-4 induced increases in ALP activity and osteocalcin mRNA levels.
Conclusions:
- FK506 promotes osteoblastic differentiation in mesenchymal cells.
- FK506 potentiates BMP-4's osteogenic effects.
- FK506 shows promise for enhancing bone tissue regeneration strategies.